Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure Portfolio News / By Karina Tin July 6, 2022
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer Portfolio News / By Karina Tin June 30, 2022
Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites Portfolio News / By Karina Tin June 30, 2022
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy Portfolio News / By Karina Tin June 29, 2022
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236 Portfolio News / By Karina Tin June 28, 2022
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022 Portfolio News / By Karina Tin June 23, 2022
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting Portfolio News / By Karina Tin June 17, 2022
Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics Portfolio News / By Karina Tin June 16, 2022
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis Portfolio News / By Karina Tin June 13, 2022
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Portfolio News / By Karina Tin June 5, 2022